Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 1.03%
- Poor long term growth as Net Sales has grown by an annual rate of -7.91% and Operating profit at 3.44% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Negative results in Mar 25
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,567 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.38
-19.84%
7.18
Revenue and Profits:
Net Sales:
163 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.5%
0%
-18.5%
6 Months
-23.27%
0%
-23.27%
1 Year
-13.89%
0%
-13.89%
2 Years
-6.47%
0%
-6.47%
3 Years
-15.19%
0%
-15.19%
4 Years
-13.63%
0%
-13.63%
5 Years
-35.76%
0%
-35.76%
Shanghai Fudan Forward S&T Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-7.91%
EBIT Growth (5y)
3.44%
EBIT to Interest (avg)
-0.21
Debt to EBITDA (avg)
6.86
Net Debt to Equity (avg)
0.41
Sales to Capital Employed (avg)
0.56
Tax Ratio
1.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.03%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.18
EV to EBIT
100.57
EV to EBITDA
56.73
EV to Capital Employed
5.48
EV to Sales
7.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
5.45%
ROE (Latest)
-19.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
163.30
158.70
2.90%
Operating Profit (PBDIT) excl Other Income
8.80
5.10
72.55%
Interest
4.10
2.50
64.00%
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-0.10
-8.20
98.78%
Operating Profit Margin (Excl OI)
-21.20%
-45.10%
2.39%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 2.90% vs -4.63% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 98.78% vs 91.91% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
636.50
670.30
-5.04%
Operating Profit (PBDIT) excl Other Income
-64.60
42.00
-253.81%
Interest
15.70
20.30
-22.66%
Exceptional Items
-10.20
-2.80
-264.29%
Consolidate Net Profit
-135.00
6.80
-2,085.29%
Operating Profit Margin (Excl OI)
-184.20%
-19.60%
-16.46%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -5.04% vs -13.82% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -2,085.29% vs 871.43% in Dec 2023
About Shanghai Fudan Forward S&T Co., Ltd. 
Shanghai Fudan Forward S&T Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






